# EDGAR Filing Document

**Accession Number:** 0001434316
**File Stem:** 0001193125-25-134875
**Filing Date:** 2025-6
**Character Count:** 17552
**Document Hash:** 4b54773ced3d7a8a3f63b8658134b1dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-134875.hdr.sgml**: 20250604

**ACCESSION NUMBER**: 0001193125-25-134875

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20250604

**DATE AS OF CHANGE**: 20250604

**EFFECTIVENESS DATE**: 20250604

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FATE THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0001434316
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 651311552
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-287765
- **FILM NUMBER:** 251023053

**BUSINESS ADDRESS:**
- **STREET 1:** 12278 SCRIPPS SUMMIT DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92131
- **BUSINESS PHONE:** 858.875.1803

**MAIL ADDRESS:**
- **STREET 1:** 12278 SCRIPPS SUMMIT DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92131

**As filed with the Securities and Exchange Commission on June 4, 2025** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## FATE THERAPEUTICS, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **65-1311552** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **12278 Scripps Summit Drive**<br> **San Diego, CA** | **92131** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**FATE THERAPEUTICS, INC. SECOND AMENDED AND RESTATED 2022 STOCK OPTION AND INCENTIVE PLAN** 

**(Full title of the plan)** 

**Bahram Valamehr, Ph.D., M.B.A.** 

**President and Chief Executive Officer** 

**Fate Therapeutics, Inc.** 

**12278 Scripps Summit Drive** 

**San Diego, CA 92131** 

**(Name and address of agent for service)** 

**(858) 875-1800**

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | |
|:---|:---|
| **Kingsley L. Taft, Esq.**<br> **Maggie L. Wong, Esq.**<br> **Natalie T. Martirossian, Esq.**<br> **Goodwin Procter LLP**<br> **525 Market Street**<br> **San Francisco, CA 94105**<br> **Telephone: (415) 733-6000** | **Cindy R. Tahl, Esq.**<br> **Chief Legal and Compliance Officer, and Corporate Secretary**<br> **Fate Therapeutics, Inc.**<br> **12278 Scripps Summit Drive**<br> **San Diego, CA 92131**<br> **Telephone: (858) 875-1800** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

On March 27, 2025, the Board of Directors of Fate Therapeutics, Inc. (the "**Company**") adopted, subject to approval by stockholders, the Fate Therapeutics, Inc. Second Amended and Restated 2022 Stock Option and Incentive Plan (the "**A&R 2022 Plan**"), which the stockholders of the Company approved at the Company's 2025 Annual Meeting of Stockholders held on May 29, 2025. The A&R 2022 Plan increased the number of shares of common stock, par value $0.001 per share, of the Company ("**Common Stock**"), authorized for issuance thereunder by 7,000,000 shares to a new total of 24,500,000 shares of Common Stock. The A&R 2022 Plan will otherwise continue in effect through its current term (June 2032), unless terminated earlier by the Company's Board of Directors.

The Company is filing this registration statement on Form S-8 (this "**Registration Statement**") solely for the purpose of registering the 7,000,000 additional shares of Common Stock authorized for issuance under the A&R 2022 Plan. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "**Securities Act**"), this Registration Statement also includes an indeterminate number of additional shares of Common Stock that may become issuable under the A&R 2022 Plan by reason of anti-dilution and other adjustments.

------

**REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E** 

Pursuant to General Instruction E of Form S-8, the Company is filing this Registration Statement with the Securities and Exchange Commission (the "**Commission**") to register an additional 7,000,000 shares of its Common Stock under the A&R 2022 Plan. Such additional shares are of the same class as other securities for which a registration statement relating to the A&R 2022 Plan has previously been filed and is effective. Pursuant to General Instruction E of Form S-8 regarding Registration of Additional Securities, the contents of the Company's Registration Statement on Form S-8 (File No. 333-265502), filed with the Commission on June 9, 2022, and the Company's Registration Statement on Form S-8 (File No. 333-280097), filed with the Commission on June 10, 2024, are hereby incorporated by reference.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

Item 8. <u>Exhibits</u>.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 4.1 | [Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference from Exhibit 3.2 to the Registrant's Amendment No. 1 to Registration Statement on Form S-1, filed on August 29, 2013, File No. 333-190608)](http://www.sec.gov/Archives/edgar/data/1434316/000119312513351036/d590580dex32.htm) |
| 4.2 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference from Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on June 7, 2021, File No. 001-36076)](http://www.sec.gov/Archives/edgar/data/1434316/000119312521184402/d191657dex31.htm) |
| 4.3 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference from Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on June 10, 2024, File No. 001-36076)](http://www.sec.gov/Archives/edgar/data/1434316/000119312524158374/d764437dex31.htm) |
| 4.4 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference from Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on May 30, 2025, File No. 001-36076)](http://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/d42374dex31.htm) |
| 4.5 | [Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock of the Registrant (incorporated by reference from Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on November 29, 2016, File No. 001-36076)](http://www.sec.gov/Archives/edgar/data/1434316/000119312516778378/d301639dex31.htm) |
| 4.6 | [Amended and Restated Bylaws of the Registrant (incorporated by reference from Exhibit 3.3 to the Registrant's Annual Report on Form 10-K, filed on February 24, 2021, File No. 001-36076)](http://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex33_493.htm) |
| 4.7 | [Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock of the Registrant (incorporated by reference from Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on April 19, 2023, File No. 001-36076)](http://www.sec.gov/Archives/edgar/data/1434316/000095017023013471/fate-ex3_1.htm) |
| 4.8 | [Specimen Common Stock Certificate (incorporated by reference from Exhibit 4.1 to the Registrant's Amendment No. 1 to Registration Statement on Form S-1, filed on August 29, 2013, File No. 333-190608)](http://www.sec.gov/Archives/edgar/data/1434316/000119312513351036/d590580dex41.htm) |
| 5.1\* | [Opinion of Goodwin Procter LLP](d50939dex51.htm) |
| 23.1\* | [Consent of Independent Registered Public Accounting Firm](d50939dex231.htm) |
| 23.2\* | [Consent of Goodwin Procter LLP (included in Exhibit 5.1)](d50939dex51.htm) |
| 24.1\* | [Power of Attorney (included on signature page)](d50939ds8.htm#sig) |
| 99.1 | [Second Amended and Restated 2022 Stock Option and Incentive Plan and form agreements thereunder (incorporated by reference from Exhibit 10.1 to the Registrant's Current Report on Form 8-K, filed on May 30, 2025, File No. 001-36076)](http://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/d42374dex991.htm) |
| 107\* | [Filing Fee Table](d50939dexfilingfees.htm) |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on this 4th day of June, 2025.

---

| | |
|:---|:---|
|  **FATE THERAPEUTICS, INC.** | **FATE THERAPEUTICS, INC.** |
| By: | /s/ Bahram Valamehr |
|  | Bahram Valamehr, Ph.D., M.B.A. |
|  | President and Chief Executive Officer |

---

------

**POWER OF ATTORNEY AND SIGNATURES** 

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby severally constitutes and appoints each of Bahram Valamehr, Ph.D., M.B.A. and Cindy R. Tahl, and each of them singly, as such person's true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in such person's name, place and stead, in any and all capacities, to sign any or all amendments (including, without limitation, post-effective amendments) to this registration statement (or any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Bahram Valamehr<br> Bahram Valamehr, Ph.D., M.B.A. | President, Chief Executive Officer and Director<br>(Principal Executive and Financial Officer) | June 4, 2025 |
| /s/ William H. Rastetter<br> William H. Rastetter, Ph.D. | Chairman of the Board and Director | June 4, 2025 |
| /s/ John D. Mendlein<br> John D. Mendlein, Ph.D., J.D. | Vice Chairman of the Board and Director | June 4, 2025 |
| /s/ Matthew C. Abernethy<br> Matthew C. Abernethy, M.B.A. | Director | June 4, 2025 |
| /s/ Michael Lee<br> Michael Lee | Director | June 4, 2025 |
| /s/ Robert S. Epstein<br> Robert S. Epstein, M.D., M.S. | Director | June 4, 2025 |
| /s/ Karin Jooss<br> Karin Jooss, Ph.D. | Director | June 4, 2025 |
| /s/ Shefali Agarwal<br> Shefali Agarwal, M.D. | Director | June 4, 2025 |
| /s/ Yuan Xu<br> Yuan Xu, Ph.D. | Director | June 4, 2025 |
| /s/ Neelufar Mozaffarian<br> Neelufar Mozaffarian, M.D., Ph.D. | Director | June 4, 2025 |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g50939g0529073304532.jpg) | Goodwin Procter LLP<br> 525 Market Street<br>San Francisco, CA 94105<br>goodwinlaw.com<br> +1 415 733 6000 |

---

June 4, 2025

Fate Therapeutics, Inc.

12278 Scripps Summit Drive

San Diego, CA 92131

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as your counsel in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 7,000,000 shares (the "Shares") of Common Stock, par value $0.001 per share ("Common Stock"), of Fate Therapeutics, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's Second Amended and Restated 2022 Stock Option and Incentive Plan (the "Plan").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

For purposes of the opinion set forth below, we have assumed that, at the time Shares are issued, the total number of then unissued Shares, when added to the number of shares of Common Stock issued, subscribed for, or otherwise committed to be issued, does not exceed the number of shares of Common Stock authorized by the Company's certificate of incorporation.

The opinion set forth below is limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered against payment therefor in accordance with the terms of the Plan, will be validly issued, fully paid and nonassessable.

------

Fate Therapeutics, Inc.

June 4, 2025

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

---

| |
|:---|
| Very truly yours, |
| /S/ GOODWIN PROCTER LLP |
| GOODWIN PROCTER LLP |

---

## Exhibit 23.1

**Exhibit 23.1** 

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Fate Therapeutics, Inc. Second Amended and Restated 2022 Stock Option and Incentive Plan of our report dated March 5, 2025, with respect to the consolidated financial statements of Fate Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Diego, California

June 3, 2025

## Ex-Filing

**Exhibit 107** 

**Calculation of Filing Fee Table** 

**FORM S-8**

(Form Type)

**Fate Therapeutics, Inc.** 

(Exact Name of Registrant as Specified in its Charter)

**Table 1: Newly Registered Securities** 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Security<br>Type | Security<br>Class Title | Fee<br>Calculation<br>Rule | Amount <br>Registered(1) | Proposed <br>Maximum <br>Offering <br>Price Per <br>Unit | Maximum<br>Aggregate<br>Offering<br> Price | Fee<br> Rate | Amount of<br>Registration Fee |
| &nbsp;&nbsp;&nbsp;Fees to be Paid | Equity | Common Stock, par value $0.001 per share | 457(c) and 457(h) | 7000000(2) | $1.27(3) | $8890000.00 | 0.00015310 | $1361.06 |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $8890000.00 |  | $1361.06 |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $1361.06 |

---

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), the
number of shares of common stock, par value $0.001 per share ("Common Stock"), of the Registrant registered hereunder includes an indeterminable number of shares of Common Stock that become issuable by reason of any share dividend, share
split or other similar transaction.

(2) Represents 7,000,000 additional shares of Common Stock issuable under the Fate Therapeutics, Inc. Second
Amended and Restated 2022 Stock Option and Incentive Plan, as approved by the Board of Directors of the Registrant on March 27, 2025 and approved by the Stockholders of the Registrant at the 2025 Annual Meeting of Stockholders on May 29,
2025. (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) under
the Securities Act on the basis of the average of the high and low sales prices of the Common Stock as reported on the Nasdaq Global Market on May 30, 2025.